title: LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
abstract: OBJECTIVE
  To investigate the association between LRP5 gene polymorphisms and response to alendronate in Chinese osteoporotic women.
  
  
  METHODS
  Six hundred and thirty nine Chinese postmenopausal women with osteopenia or osteoporosis were included and received alendronate treatment. The A1330V polymorphism of LRP5 was investigated. Bone mineral density (BMD) and bone turnover markers (ALP and β-isomerized carboxy-telopeptide of type I collagen [β-CTX]) were measured before and after treatment. The correlation of LRP5 polymorphisms with changes in BMD and bone turnover biomarkers were analyzed after treatment.
  
  
  RESULTS
  After 12 months of treatment, participants with CC and CT genotypes had a larger increase in lumbar spine BMD and a larger decrease in serum β-CTX and ALP levels than those with TT genotype (all p < 0.001). No significant genotype-treatment interaction was found in hip BMD.
  
  
  CONCLUSIONS
  The A1330V polymorphism of LRP5 is possibly correlated with response to alendronate treatment in Chinese women with osteoporosis, and the TT genotype could possibly predict a weak response to alendronate.
authors.affiliation: Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing 100730, China.
authors.forename: Pei Ran
authors.initials: PR
authors.lastname: Zhou
authors.forename: Hai Juan
authors.initials: HJ
authors.lastname: Liu
authors.forename: Er Yuan
authors.initials: EY
authors.lastname: Liao
authors.forename: Zhen Lin
authors.initials: ZL
authors.lastname: Zhang
authors.forename: De Cai
authors.initials: DC
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Liu
authors.forename: Wen
authors.initials: W
authors.lastname: Wu
authors.forename: Xiao Ping
authors.initials: XP
authors.lastname: Xing
authors.forename: Wei Bo
authors.initials: WB
authors.lastname: Xia
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.forename: Mei
authors.initials: M
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects / Q000235:genetics; D024042:Collagen Type I / Q000235:genetics / Q000378:metabolism; D005260:Female; D005838:Genotype; D006801:Humans; D060492:Low Density Lipoprotein Receptor-Related Protein-5 / Q000235:genetics* / Q000378:metabolism; D008159:Lumbar Vertebrae / Q000187:drug effects; D008875:Middle Aged; D010012:Osteogenesis / Q000187:drug effects / Q000235:genetics; D010024:Osteoporosis / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D011110:Polymorphism, Genetic / Q000235:genetics*; D017698:Postmenopause / Q000187:drug effects* / Q000235:genetics* / Q000378:metabolism
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; C555482:LRP5 protein, human; D060492:Low Density Lipoprotein Receptor-Related Protein-5; D019386:Alendronate
keywords: A1330V polymorphism; LRP5 gene; alendronate; osteoporosis; response to treatment